Background: While the reaction history is critical for drug allergy evaluations and is typically self-reported, there is no validated survey instrument to collect drug allergy history from patients.
Objective: To validate a survey instrument that collects patient-reported drug allergy history.
Methods: The Drug Allergy History Tool (DAHT) was revised after three rounds of cognitive testing, with data assessed for reliability, through test-retest comparison, and quality and validity, through a concordance analysis against electronic health record (EHR) allergist documentation. Participants completing testing and surveys were recruited from drug allergy clinics at Massachusetts General Hospital. Primary evaluative measures were percent agreement and Kappa statistic values.
Results: The DAHT was completed by 79 individuals (mean age 49 [SD 17] years, 85% Female, 85% White, 11% Hispanic ethnicity); 29 with single-drug allergy labels and 50 with multiple drug allergy labels. The most common drug allergy labels were penicillins (77%), sulfonamides (32%), cephalosporins (15%), and nonsteroidal anti-inflammatory drugs (8%). DAHT achieved acceptable test-retest reliability (median Kappa = 0.64, median percent agreement = 86%). The DAHT achieved a more complete allergy history than the allergist documentation in the EHR with lower median item uncertainty (21% DAHT vs 79% EHR) with fair concordance (median Kappa = 0.21, median percent agreement = 67%) between the two data sources.
Conclusion: The DAHT is a reliable and valid source of patient-reported allergy information. This tool can be used in clinical care and clinical research to obtain standardized patient reported drug allergy history.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaci.2025.02.027 | DOI Listing |
Contact Dermatitis
March 2025
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, INFLA-MED Centre of Excellence, University of Antwerp, Antwerp, Belgium.
Biol Pharm Bull
March 2025
Division of Drug Informatics, Keio University Faculty of Pharmacy, Minato-ku, Tokyo 105-8512, Japan.
Iodine-based contrast agents can induce various acute hypersensitivity reactions ranging from mild itching or vomiting shortly after administration to severe hypotension or loss of consciousness. In Japan, steroid premedication is commonly used to prevent acute hypersensitivity reactions. However, little clear evidence supporting its efficacy is available.
View Article and Find Full Text PDFKeio J Med
March 2025
Division of Social Pharmacy, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Undernutrition is a common risk after surgery or during periods when oral dietary intake is challenging. Enteral nutrients, frequently utilized in nutritional management, are drugs associated with multiple contraindications involving pathology and allergy, and they require careful attention in dispensing. However, the occurrence of nutrition-related incidents in community pharmacies remains unknown.
View Article and Find Full Text PDFJ Immunother Cancer
March 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.
View Article and Find Full Text PDFJ Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!